Lung Cancer Mutation Consortium LEADER Trial Enrolls 100th Patient

First Major Milestone Met in Trial to Inform Neoadjuvant Targeted Therapy Options for Early-Stage Lung Cancer Patients

NEW YORK, Oct. 24, 2023 /PRNewswire/ -- The Lung Cancer Mutation Consortium (LCMC), facilitated by the Lung Cancer Research Foundation (LCRF), announces the enrollment of one hundred patients in its fourth study, LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer (LEADER), examining targeted drugs given as single agents and combinations as neoadjuvant therapies matched to specific genetic mutations.

This is the first of the LEADER trial's major milestones to be met, with many more to come. Seventeen sites are currently enrolling patients in the study with more sites expected to join the trial.

The LEADER trial, together with matched industry-sponsored therapeutic trials, aims to develop data that will support oncologists in their targeted treatment planning for cancer patients prior to surgery by screening for eleven actionable driver mutations in patients.

"We're incredibly excited to have met this first major milestone in patient accrual. The importance of this study to patients with early-stage lung cancers cannot be overstated. Expanding the benefit of targeted treatment to this group can have a marked impact on patient care," says Mark G. Kris, MD, Attending Physician, Thoracic Oncology Service, Department of Medicine at Memorial Sloan Kettering Cancer Center and one of the investigators of the LEADER trial.

Patients with early-stage lung cancers who are interested in participating in the LCMC LEADER trial should discuss the study with their oncologist to determine eligibility and the process for enrollment.

To learn more about LCRF and its grants program, visit www.lcrf.org
To learn more about LCMC and the LEADER trial, visit LCRF.org/LCMC4

About the Lung Cancer Research Foundation (LCRF)
The Lung Cancer Research Foundation^® (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer. LCRF's mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer. To date, LCRF has funded 409 research grants, totaling nearly $42 million, the highest amount provided by a nonprofit organization dedicated to funding lung cancer research. For more information, visit lcrf.org.

About the Lung Cancer Mutation Consortium (LCMC)
The Lung Cancer Mutation Consortium (LCMC) is an association of more than twenty U.S. cancer centers, focused on deepening our understanding of genetic changes that lie within lung cancers. By doing so they aim to improve outcomes in patients whose tumors harbor specific oncogenic drivers. LCMC investigators match patients with targeted drugs and clinical trials based on genetic changes found through the testing of tumor tissues. This changes the standard of thoracic oncology practices today. The Lung Cancer Research Foundation coordinates and supports the activities of the LCMC. This collaboration focuses on bringing together advocacy, academic, and industry partners. This unique model streamlines research efforts, reduces costs and delays by facilitating connections across the lung cancer community and brings us closer to the goal of precision medicine where therapies are matched to specific needs of each person with lung cancer.

Contact:
Sheila Sullivan
Sr. Director, Marketing & Communications, LCRF
[email protected]

SOURCE Lung Cancer Research Foundation